NEW YORK (GenomeWeb News) – Rosetta Genomics said yesterday that it has completed its previously announced direct offering of approximately $5.1 million in securities.

Rosetta has received net proceeds of approximately $4.5 million after deducting placement agent fees and other offering expenses.

The molecular diagnostics developer said that it plans to use the $4.5 million in proceeds from the offering for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.